| HR (95% CI) | p-value |
---|---|---|
Mortality | ||
 Validation cohort | 1.085 (0.886–1.328) | 0.429 |
  1 | 0.298 (0.237–0.376) | <0.001 |
  2 | 0.932 (0.768–1.131) | 0.476 |
  3 | 1.379 (0.640–2.974) | 0.412 |
  4 | 0.122 (9.058–0.257) | <0.001 |
  5 | 0.604 (0.281–1.300) | 0.197 |
  6 | 0.989 (0.723–1.354) | 0.945 |
  7 | Ref. |  |
 interactions | ||
  V 1 | 1.766 (0.948–3.291) | 0.073 |
  V 2 | 0.942 (0.721–1.230) | 0.658 |
  V 3 | 1.129 (0.480–2.655) | 0.782 |
  V 4 | 0.526 (0.107–2.587) | 0.429 |
  V 5 | 0.878 (0.285–2.710) | 0.821 |
  V 6 | 0.886 (0.553–1.418) | 0.614 |
  V 7 | Ref. |  |
RRT inception | ||
 Validation cohort | 1.196 (0.705–2.029) | 0.508 |
  1 | 0.308 (0.208–0.455) | <0.001 |
  2 | Ref. |  |
  3 | 3.848 (2.726–5.433) | <0.001 |
  4 | 0.876 (0.531–1.446) | 0.605 |
  5 | 0.948 (0.470–1.914) | 0.882 |
  6 | 0.395 (0.244–0.640) | <0.001 |
  7 | 0.442 (0.262–0.744) | 0.002 |
 interactions | ||
  V 1 | 0.765 (0.383–1.530) | 0.449 |
  V 2 | Ref. |  |
  V 3 | 0.567 (0.247–1.301) | 0.181 |
  V 4 | 0.441 (0.257–0.756) | 0.003 |
  V 5 | 0.230 (0.080–0.663) | 0.007 |
  V 6 | 0.379 (0.155–0.929) | 0.034 |
  V 7 | 0.389 (0.183–0.827) | 0.014 |